Drug discovery for malaria: a very challenging and timely endeavor.

The prevalence of resistance to known antimalarial drugs has resulted in the expansion of antimalarial drug discovery efforts. Academic and nonprofit institutions are partnering with the pharmaceutical industry to develop new antimalarial drugs. Several new antimalarial agents are undergoing clinical trials, mainly those resurrected from previous antimalarial drug discovery programs. Novel antimalarials are being advanced through the drug development process, of course, with the anticipated high failure rate typical of drug discovery. Many of these are summarized in this review. Mechanisms for funding antimalarial drug discovery and genomic information to aid drug target selection have never been better. It remains to be seen whether ongoing efforts will be sufficient for reducing malaria burden in the developing world.

[1]  T. Shapiro,et al.  Second generation, orally active, antimalarial, artemisinin-derived trioxane dimers with high stability, efficacy, and anticancer activity. , 2006, Journal of medicinal chemistry.

[2]  Christian Scheurer,et al.  Identification of an antimalarial synthetic trioxolane drug development candidate , 2004, Nature.

[3]  David K Williams,et al.  Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. , 2005, Journal of medicinal chemistry.

[4]  J. Derisi,et al.  Parallel synthesis of 9-aminoacridines and their evaluation against chloroquine-resistant Plasmodium falciparum. , 2006, Bioorganic & medicinal chemistry.

[5]  P. O’Neill,et al.  Knowledge of the proposed chemical mechanism of action and cytochrome p450 metabolism of antimalarial trioxanes like artemisinin allows rational design of new antimalarial peroxides. , 2004, Accounts of chemical research.

[6]  Timothy S. Ham,et al.  Production of the antimalarial drug precursor artemisinic acid in engineered yeast , 2006, Nature.

[7]  Parallel synthesis and antimalarial screening of a 4-aminoquinoline library. , 2004, Journal of combinatorial chemistry.

[8]  D. Boykin,et al.  CYP4F Enzymes Are the Major Enzymes in Human Liver Microsomes That Catalyze the O-Demethylation of the Antiparasitic Prodrug DB289 [2,5-Bis(4-amidinophenyl)furan-bis-O-methylamidoxime] , 2006, Drug Metabolism and Disposition.

[9]  P. Rathod,et al.  Resistance to a Protein Farnesyltransferase Inhibitor in Plasmodium falciparum* , 2005, Journal of Biological Chemistry.

[10]  I. Bathurst,et al.  Medicines for Malaria Venture: sustaining antimalarial drug development. , 2006, Trends in parasitology.

[11]  Solomon Nwaka,et al.  Innovative lead discovery strategies for tropical diseases , 2006, Nature Reviews Drug Discovery.

[12]  A. Dreisbach,et al.  Randomized Dose-Ranging Controlled Trial of AQ-13, a Candidate Antimalarial, and Chloroquine in Healthy Volunteers , 2007, PLoS clinical trials.

[13]  D. Boykin,et al.  Accumulation and Intracellular Distribution of Antitrypanosomal Diamidine Compounds DB75 and DB820 in African Trypanosomes , 2006, Antimicrobial Agents and Chemotherapy.

[14]  H. Vial,et al.  Antimalarial activity of compounds interfering with Plasmodium falciparum phospholipid metabolism: comparison between mono- and bisquaternary ammonium salts. , 2000, Journal of medicinal chemistry.

[15]  S. Krishna,et al.  Artemisinins target the SERCA of Plasmodium falciparum , 2003, Nature.

[16]  S. Meshnick,et al.  Efficacy of DB289 in Thai patients with Plasmodium vivax or acute, uncomplicated Plasmodium falciparum infections. , 2005, The Journal of infectious diseases.

[17]  H. Vial,et al.  Prodrugs of bisthiazolium salts are orally potent antimalarials. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Ruth H. Hughes,et al.  Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials. , 2003, Journal of medicinal chemistry.

[19]  H. Vial,et al.  A Class of Potent Antimalarials and Their Specific Accumulation in Infected Erythrocytes , 2002, Science.

[20]  Angus Cameron,et al.  A single amino acid residue can determine the sensitivity of SERCAs to artemisinins , 2005, Nature Structural &Molecular Biology.

[21]  S. Croft,et al.  Public-private partnership: from there to here. , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.